Health Care·Pharmaceuticals·$4.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.60 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.60 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management's commentary indicated a cautious approach as they continue to develop their pipeline. There was no specific guidance provided for future performance.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The focus remains on advancing their clinical programs.
Crinetics Pharmaceuticals reported a loss of $0.60 per share, but did not disclose revenue figures or future guidance. The stock fell by 1.82%, reflecting investor uncertainty due to the lack of detailed financial metrics and outlook. The company's focus remains on its clinical programs, but the absence of guidance may lead to cautious sentiment among investors.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
UGI CORP NEW
Nov 11, 2019